Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells

Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.

Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.

Munshi, N. C., Anderson, L. D., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2024850 · Cited by 2,560

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.

Berdeja, J. G., Madduri, D., Usmani, S. Z., Jakubowiak, A., Agha, M., Cohen, A. D., Stewart, A. K., Hari, P., Htut, M., Lesokhin, A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00933-8 · Cited by 1,756

Engineering strategies to overcome the current roadblocks in CAR T cell therapy

Rafiq, S., Hackett, C. S., & Brentjens, R. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0297-y · Cited by 1,525

Teclistamab in Relapsed or Refractory Multiple Myeloma

Moreau, P., Garfall, A. L., van de Donk, N. W. C. J., Nahi, H., San-Miguel, J. F., Oriol, A., Nooka, A. K., Martin, T., Rosinol, L., Chari, A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203478 · Cited by 1,269

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.

Lonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A.-O., Callander, N., Lendvai, N., Sborov, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30788-0 · Cited by 812

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

Kumar, S. K., Lee, J. H., Lahuerta, J. J., Morgan, G., Richardson, P. G., Crowley, J., Haessler, J., Feather, J., Hoering, A., Moreau, P., et al. (2012) · Leukemia · doi:10.1038/leu.2011.196 · Cited by 721

B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma

Carpenter, R. O., Evbuomwan, M. O., Pittaluga, S., Rose, J. J., Raffeld, M. A., Yang, S., Gress, R. E., Hakim, F. T., & Kochenderfer, J. N. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2422 · Cited by 667

Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up

Martin, T., Usmani, S. Z., Berdeja, J. G., Agha, M., Cohen, A. D., Hari, P., Avigan, D., Deol, A., Htut, M., Lesokhin, A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.00842 · Cited by 663

Targeting B Cell Maturation Antigen in Patients with Multiple Myeloma: Current Perspectives

Shrivastava, T., van Rhee, F., & Hadidi, S. A. (2023) · OncoTargets and Therapy · doi:10.2147/ott.s370880 · Cited by 13

The Evolving Landscape in Multiple Myeloma: From Risk Stratification to T Cell-Directed Advanced Therapies

Besliu, C., Tănase, A., Rotaru, I., Espinoza, J., Vidal, L., Poelman, M., Juan, M., de Larrea, C. F., & Saini, K. S. (2025) · Cancers · doi:10.3390/cancers17030525 · Cited by 15

Under the Hood: Evidence-Based Review of Allogeneic Chimeric Antigen Receptor T Cells for Hematologic Malignancies

Cheema, A. Y., Ali, H. M., Bibi, M., Aslam, M. F., Thiagarajan, P. S., Shahid, D., Munir, M., Najam, A., Raza, S., & Anwer, F. (2025) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2025.09.044 · Cited by 14

Preclinical activity of allogeneic SLAMF7-specific CAR T-cells (UCARTCS1) in multiple myeloma

Korst, C. L. B. M., O’Neill, C. A., Bruins, W. S. C., Cosovic, M., Twickler, I., Verkleij, C. P. M., Clerre, D. L., Themeli, M., Chion-Sotinel, I., Zweegman, S., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008769 · Cited by 13

Glutamine-driven metabolic reprogramming promotes CAR-T cell function through mTOR-SREBP2 mediated HMGCS1 upregulation in ovarian cancer

Chen, J., Zhao, L., Li, W., Wang, S., Li, J., Lv, Z., Zhao, Y., Liang, J., Hu, Z., Pan, F., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06853-0 · Cited by 12

Off-the-shelf CAR T cells for multiple myeloma

Brudno, J. N., & Kochenderfer, J. N. (2023) · Nature Medicine · doi:10.1038/s41591-022-02195-2 · Cited by 12

BCMA CAR-T cells in multiple myeloma–ready for take-off?

Scheller, L., Tebuka, E., Rambau, P., Einsele, H., Hudecek, M., Prommersberger, S., & Danhof, S. (2023) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2023.2276676 · Cited by 14

Mechanisms of Resistance to CAR T-Cells and How to Overcome Them

Legato, L., Bisio, M., Fasano, F., Savelli, C. B., Secreto, C., Dellacasa, C. M., Botto, B., Busca, A., Cerrano, M., Freilone, R., et al. (2025) · Methods and Protocols · doi:10.3390/mps8050108 · Cited by 14

Therapeutic targeting of the protein tyrosine kinase-7 in cancer: an overview

Mottard, K., Cokaiko, J., Rogister, B., & Neirinckx, V. (2024) · The Oncologist · doi:10.1093/oncolo/oyae290 · Cited by 11

CAR T cell therapy in multiple myeloma, where are we now and where are we heading for?

Fischer, L., Grieb, N., Platzbecker, U., Vučinić, V., & Merz, M. (2023) · European Journal of Haematology · doi:10.1111/ejh.14051 · Cited by 11

Harnessing the potential of gene editing technology for CAR-T cell therapy of solid tumors

Khodabandehloo, E., Rayati, M., Ahmadi, E., Naghdibadi, M., Moradi, V., & Ahmadbeigi, N. (2025) · Inflammation and Regeneration · doi:10.1186/s41232-025-00398-x · Cited by 13

Harnessing Targeted Photodynamic Therapy to Synergistically Activate T Cell and NK Cell Responses in Multiple Myeloma

Liu, Z., Liu, X., Ma, J., Zhang, Y., Ye, M., Liu, H., Ding, K., Song, J., Fu, R., & Qi, J. (2025) · Advanced Materials · doi:10.1002/adma.202518663 · Cited by 10

Allogeneic CAR-T cells for cancer immunotherapy

Chen, X., Gao, Y., & Zhang, Y. (2024) · Immunotherapy · doi:10.1080/1750743x.2024.2408048 · Cited by 10

Chimeric antigen receptor–modified T-cell therapy: Recent updates and challenges in autoimmune diseases

Caël, B., Bôle‐Richard, E., Garnache‐Ottou, F., & Aubin, F. (2024) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2024.12.1066 · Cited by 13

An Assessment of the Effectiveness and Safety of Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma Patients with Relapsed or Refractory Disease: A Systematic Review and Meta-Analysis

Pereira, R., & Bergantim, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094996 · Cited by 10

Anti-BCMA CAR-T cell-based therapies and bispecific antibodies in the immunotherapy era: are we ready for this?

Martino, M., Gamberi, B., Antonioli, E., Aquino, S., Pepa, R. D., Malerba, L., Mangiacavalli, S., Pezzatti, S., Bringhen, S., & Zamagni, E. (2024) · Expert Review of Hematology · doi:10.1080/17474086.2024.2357274 · Cited by 10

Chimeric antigen receptor T-cells: a review on current status and future directions for relapsed/refractory multiple myeloma

Hamadeh, I., Friend, R., Mailankody, S., & Atrash, S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1455464 · Cited by 9

CAR T-cell therapy to treat multiple myeloma: current state and future directions

Reddy, S. T., Hosoya, H., & Mikkilineni, L. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10219-1 · Cited by 10

Overcoming cancer immunotherapy barriers via nanomaterial-mediated pyroptosis

Xie, J., Peng, B., Xiao, Y., Chen, X., Zhang, X., Chen, D., Song, L., Xu, M., Liao, W., & Zhang, X. (2025) · Journal of Materials Chemistry B · doi:10.1039/d5tb01024a · Cited by 10

TSCM-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial

Tseng, H., Dholaria, B., Cranert, S. A., Richter, M., Marquez, K., Cho, B. S., Bacong, A., McArthur, K., Eskew, J. D., McCaigue, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-65267-0 · Cited by 10

T cell immunotherapy for solid tumors: limitations, progress, and future prospects

Wang, Y., Zhang, B., Wang, Y., Tan, Y., Hu, X., Che, X., & Feng, M. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1755751 · Cited by 11

Update on the current and future use of CAR‐T to treat multiple myeloma

Gahvari, Z. J., Brunner, M., Schmidt, T. M., & Callander, N. S. (2023) · European Journal Of Haematology · doi:10.1111/ejh.14145 · Cited by 9

Chimeric antigen receptor T‐cell therapy for haematological malignancies: Insights from fundamental and translational research to bedside practice

Grégoire, C., de Oliveira, B. C., Caimi, P. F., Caers, J., & Melenhorst, J. J. (2024) · British Journal of Haematology · doi:10.1111/bjh.19751 · Cited by 12

Idecabtagene Vicleucel Is Well Tolerated and Effective in Relapsed/Refractory Myeloma Patients with Prior Allogeneic Stem Cell Transplantation

John, L., Sauer, S., Hegenbart, U., Dreger, P., Hundemer, M., Müller‐Tidow, C., Schmitt, A., Schmitt, M. W., Raab, M. S., & Schönland, S. O. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.06.010 · Cited by 9

Integrating Immune Therapies for the Treatment of Multiple Myeloma.

Mikkilineni, L., & Sidana, S. (2023) · The Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.7100 · Cited by 7

Overexpression of an Engineered SERPINB9 Enhances Allogeneic T-cell Persistence and Efficacy

Teo, P. Y., Jung, Y., Quach, D. H., Koh, J., Ong, R., Goh, A. X., Tan, A. S. M., Ng, C. H., Seh, C. C., Tan, K. W., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-1001 · Cited by 8

Allogeneic and other innovative chimeric antigen receptor platforms

Jallouk, A. P., Sengsayadeth, S. M., Savani, B. N., Dholaria, B., & Oluwole, O. O. (2024) · Clinical Hematology International · doi:10.46989/001c.121404 · Cited by 8

CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial

Xu, Y., Zhang, X., Xin, D., Zhang, J., Wang, L., Fan, Y., Chen, B., Lei, W., Qiu, X., Jiang, H., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-0051 · Cited by 8

Alloreactive-free CAR-VST therapy: a step forward in long-term tumor control in viral context

Wang, V., Savoldo, B., Guimaraes, J.-A., Dotti, G., Reppel, L., & Bensoussan, D. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1527648 · Cited by 8

Expanding Immunotherapy Beyond CAR T Cells: Engineering Diverse Immune Cells to Target Solid Tumors

Andreou, T., Neophytou, C., Mpekris, F., & Stylianopoulos, T. (2025) · Cancers · doi:10.3390/cancers17172917 · Cited by 8

Has the shortage of fludarabine altered the current paradigm of lymphodepletion in favor of bendamustine?

Filioglou, D., Husnain, M., Khurana, S., Simpson, R. J., & Katsanis, E. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1329850 · Cited by 8

Cellular Therapies for Multiple Myeloma: Engineering Hope

Vera-Cruz, S., Culubret, M., Konetzki, V., Alb, M., Friedel, S. R., Hudecek, M., Einsele, H., Danhof, S., & Scheller, L. (2024) · Cancers · doi:10.3390/cancers16223867 · Cited by 9

Human pluripotent stem cell-derived innate and adaptive immune cells for cancer immunotherapy

Shah, Z., Tian, L., Caligiuri, M. A., Kaufman, D. S., & Yu, J. (2026) · Cell stem cell · doi:10.1016/j.stem.2025.12.017 · Cited by 7

Stealth designs to overcome allorejection in engineered cell therapy

Li, Y.-R., Chen, Y., & Yang, L. (2026) · Trends in Immunology · doi:10.1016/j.it.2026.02.008 · Cited by 9

THE ROLE OF CAR T-CELL THERAPY IN THE ERA OF BISPECIFIC ANTIBODIES

Nath, K. D., Mailankody, S., & Usmani, S. Z. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.05.011 · Cited by 8

Cytidine triphosphate synthase 1-mediated metabolic reprogramming promotes proliferation and drug resistance in multiple myeloma

Huang, H.-Y., Chen, Y., Li, Y., Zheng, X., Shu, L., Tian, L., Lin, H., & Yang, L. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e33001 · Cited by 7

Are we there yet? CAR ‐T therapy in multiple myeloma

Mirvis, E., & Benjamin, R. (2024) · British Journal of Haematology · doi:10.1111/bjh.19896 · Cited by 8

Current Main Topics in Multiple Myeloma

Morè, S., Corvatta, L., Manieri, V. M., Olivieri, A., & Offidani, M. (2023) · Cancers · doi:10.3390/cancers15082203 · Cited by 8

A safety review of recently approved and emerging drugs for patients with relapsed or refractory multiple myeloma

Midha, S., Hartley-Brown, M. A., Mo, C. C., Hossain, S., Nadeem, O., O’Donnell, E., Bianchi, G., Sperling, A. S., Laubach, J. P., & Richardson, P. G. G. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2274420 · Cited by 7

The preclinical discovery and clinical development of ciltacabtagene autoleucel (Cilta-cel) for the treatment of multiple myeloma

Straßl, I., & Podar, K. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2319672 · Cited by 8

Low platelet counts and low CD4/CD8 ratios at apheresis increase the risk of CAR T-cell manufacturing failure in myeloma

Jo, T., Yoshihara, K., Ri, M., Tsukada, N., Mimura, N., Fujii, K., Fukushima, K., Fujiwara, S., Shimura, Y., Haraguchi, K., et al. (2024) · Blood Neoplasia · doi:10.1016/j.bneo.2024.100051 · Cited by 7

Cellular Kinetics and Biodistribution of Adoptive T Cell Therapies: from Biological Principles to Effects on Patient Outcomes

Li, R., Grosskopf, A. K., Joslyn, L. R., Stefanich, E. G., & Shivva, V. (2025) · The AAPS Journal · doi:10.1208/s12248-025-01017-w · Cited by 6

From intracellular drivers to immune modulators: emerging paradigms in oncogenic pathway-directed immunotherapy optimization

Rao, D., Wang, T., Fu, C., Luo, Y., Lu, J., Sun, Z., Yan, W., Liang, H., Xia, L., & Huang, W. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02465-9 · Cited by 7

Sodium valproate drives propionylation-mediated epigenetic reprogramming to enhance mesothelin CAR-T cell therapy in solid tumors

Chen, J., Li, W., Wang, S., Li, J., Zhao, L., Ao, X., Wang, W., Zhu, L., Rao, H., Xu, S., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.12.021 · Cited by 7

Chimeric Antigen Receptor T Cells: Immunotherapy for the Treatment of Leukemia, Lymphoma, and Myeloma

de Montes, A. L. R. G., & Spencer, L. M. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0043 · Cited by 8

Preclinical delayed toxicity studies of BCMA CAR T-cell injection in B-NDG mice with multiple myeloma

Guo, J., Wu, Q., Li, H., Liang, C., Dai, J., Zhang, S., Dai, C., Zhang, J., Wen, Y., & Yang, W. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1435934 · Cited by 6

CAR-based cell therapies for systemic lupus erythematosus

Wang, Y., Lu, L., Ye, S., & Fu, Q. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003406 · Cited by 6

Autologous stem cell transplant in fit patients with refractory or early relapsed diffuse large B-cell lymphoma that responded to salvage chemotherapy

Tun, A. M., Wang, Y., Maliske, S. M., Micallef, I. N., Inwards, D. J., Habermann, T. M., Porrata, L. F., Paludo, J., Villasboas, J. C., Rosenthal, A. C., et al. (2024) · Haematologica · doi:10.3324/haematol.2023.284704 · Cited by 6

Prognostic, immunity, stemness, and anticancer drug sensitivity characterization of pyroptosis related genes in non‐small cell lung cancer

Xu, C., Ma, H., Chen, J., Li, X., Wang, Z., Hu, B., Zhang, N., & Meng, F. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.15180 · Cited by 5

B7-H3–Targeting Chimeric Antigen Receptors Epstein-Barr Virus–specific T Cells Provides a Tumor Agnostic Off-The-Shelf Therapy Against B7-H3–positive Solid Tumors

Yeo, S. P., Kua, L. H., Tan, J. W., Lim, J. K., Wong, F. H., Santos, M. D., Poh, C. M., Goh, A. X., Koh, X. Y., Zhou, X., et al. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0538 · Cited by 6

Generating advanced CAR-based therapy for hematological malignancies in clinical practice: targets to cell sources to combinational strategies

Zhou, S., Yang, Y., Jing, Y., & Zhu, X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1435635 · Cited by 5

Implementation of a CAR-T cell therapy program in India

Hotchandani, H., Sengar, M., Shetty, A., John, A., Karulkar, A., Kalra, D., Ravikumar, S., Jaiswal, A., Yadav, Y., Parkar, S., et al. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2501744 · Cited by 5

CAR-T in cancer therapeutics and updates

Zhu, S. (2024) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2024.01.001 · Cited by 5

Advances in research on factors affecting chimeric antigen receptor T‐cell efficacy

Zhou, D., Zhu, X., & Xiao, Y. (2024) · Cancer Medicine · doi:10.1002/cam4.7375 · Cited by 5

Advancement in “Off-the-Shelf” CAR T-Cell Therapy for Cancer Immunotherapy

Sheykhhasan, M., La’ah, A. S., Ahmadieh-Yazdi, A., Yang, P., Tanzadehpanah, H., Mahaki, H., Manoochehri, H., Poondla, N., Kalhor, N., & Al-Musawi, S. (2024) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/979-8-3693-3976-3.ch002 · Cited by 5

Review of CAR T-Cell Therapy in Multiple Myeloma: A Canadian Perspective

Shih, S. C.-M., & Bhella, S. (2024) · Current Oncology · doi:10.3390/curroncol31070292 · Cited by 4

Efficacy and safety of chimeric antigen receptor T cells targeting BCMA and GPRC5D in relapsed or refractory multiple myeloma

Yang, X., Wang, F., Yuan, X., Yang, B., Chen, J., Cheng, J., Liu, G., Tang, D., Xu, X., Wang, S., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1466443 · Cited by 4

Cardiovascular complications and their association with short‐ and long‐term outcomes in patients with multiple myeloma undergoing chimeric antigen receptor T‐cell therapy

Zadok, O. I. B., Simitsis, P., Jacobson, C. A., Nadeem, O., Frigault, M. J., Raje, N. S., Duffy, C., Costello, P., Cruz, J. D., Looka, A., et al. (2025) · British Journal of Haematology · doi:10.1111/bjh.70216 · Cited by 4

CAR-T cell therapy: A therapeutic strategy for cancer treatment

Sharif, S., Sharma, U., & Yadav, A. K. (2025) · Seminars in Oncology · doi:10.1016/j.seminoncol.2025.152430 · Cited by 4

Chimeric Antigen Receptor T Cells in the Treatment of Multiple Myeloma

Hasanali, Z. S., Razzo, B. M., Susanibar-Adaniya, S. P., Garfall, A. L., Stadtmauer, E. A., & Cohen, A. D. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.12.004 · Cited by 5

Advanced strategies in improving the immunotherapeutic effect of CAR‐T cell therapy

Wang, M., Jia, L., Dai, X., & Zhang, X. (2024) · Molecular Oncology · doi:10.1002/1878-0261.13621 · Cited by 5

Accelerating accessibility of CAR-T/NK therapies – Are AlloCARs and rapid manufacturing platforms the road ahead in improving access in multiple myeloma?

Rajeeve, S., Hoskote, A., & Mailankody, S. (2024) · Seminars in Hematology · doi:10.1053/j.seminhematol.2024.09.001 · Cited by 5

Into the storm: the imbalance in the yin-yang immune response as the commonality of cytokine storm syndromes

Armstrong, A., Tang, Y., Mukherjee, N. Z., Zhang, N., & Huang, G. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1448201 · Cited by 4

Regulatory cell therapy for kidney transplantation and autoimmune kidney diseases

Ho, Q. Y., Hester, J., & Issa, F. (2024) · Pediatric Nephrology · doi:10.1007/s00467-024-06514-2 · Cited by 4

Discovery of a pan anti-SARS-CoV-2 monoclonal antibody with highly efficient infected cell killing capacity for novel immunotherapeutic approaches

Moussa, D. A., Vazquez, M., Chable-Bessia, C., Roux-Portalez, V., Tamagnini, E., Pedotti, M., Simonelli, L., Ngo, G., Souchard, M., Lyonnais, S., et al. (2024) · Emerging Microbes & Infections · doi:10.1080/22221751.2024.2432345 · Cited by 4

Novel Approaches of Cellular Therapy in Multiple Myeloma: Focus on Chimeric Antigen Receptor T-Cells

Narra, R., Peshin, S., & Dhakal, B. (2024) · Acta Haematologica · doi:10.1159/000543265 · Cited by 5

Mini-TCRs: Truncated T cell receptors to generate T cells from induced pluripotent stem cells

Takayanagi, S., Wang, B., Hasegawa, S., Nishikawa, S., Fukumoto, K. I., Nakano, K., Chuganji, S., Kato, Y., Kamibayashi, S., Minagawa, A., et al. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.101109 · Cited by 4

A bibliometric and knowledge-map study of CAR-T cell-related cytokine release syndrome (CRS) from 2012 to 2023

Li, H., Huang, Q., & Zhang, Y. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2291900 · Cited by 4

Management of relapsed refractory multiple myeloma: Evidence-based guide to community oncologists

Mushtaq, A. H., Cheema, A. Y., Ali, H. M., Shatnawi, Y., Ashruf, O. S., Ahmad, E. N., Lytvynova, O., Munir, M., Asif, M. A., Ahmad, M., et al. (2025) · Blood Reviews · doi:10.1016/j.blre.2025.101339 · Cited by 4

Reshaping multiple myeloma treatment: recent breakthroughs

Martino, E. A., Caserta, S., Vigna, E., Bruzzese, A., Mendicino, F., Alvaro, M. E., Labanca, C., Lucia, E., Olivito, V., Amodio, N., et al. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2610373 · Cited by 4

Advancements and expanding applications of CAR-T cell therapy

Zhang, X., Liu, Z.-C., Luo, L.-J., Wu, Y., Cui, X.-G., & Chen, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1802718 · Cited by 3

Applications of genome editing technologies in the treatment of human diseases

Alshorman, J., Mehran, M. J., Tembo, K. M., Mostafavi, N., Bolideei, M., & Wang, Y. L. (2026) · Gene Therapy · doi:10.1038/s41434-026-00627-z · Cited by 3

CAR-T Therapy in Multiple Myeloma: Looking Beyond

Maiorana, G., Antolino, G., Verde, G. L., & Tafuri, A. (2024) · Hemato · doi:10.3390/hemato5020015 · Cited by 4

Allogeneic chimeric antigen receptors (CARs) as an “off-the-shelf” therapy in multiple myeloma

Carlson, S. G., Lin, T. L., & Larson, S. M. (2025) · Immunotherapy · doi:10.1080/1750743x.2025.2461987 · Cited by 4

CAR-T Cell Therapy for Cancer

Al-Janabi, I. I. (2024) · Al-Rafidain Journal of Medical Sciences · doi:10.54133/ajms.v6i2.726 · Cited by 3

Hypoimmune CD19 CAR T cells treat allogeneic mice with features of spontaneous systemic lupus erythematosus

Hu, X., White, K. A., Olroyd, A. G., Friera, A. M., Wang, C., Caruso, C. B., Connolly, A. J., Deuse, T., & Schrepfer, S. (2025) · iScience · doi:10.1016/j.isci.2025.112806 · Cited by 3

CAR-T cell therapy for patients with extramedullary multiple myeloma：Opportunities and challenges

Wang, Y., Hu, X., Du, J., & Liu, B. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115374 · Cited by 2

Exposure to the immune system during bridging radiotherapy for Car-T cells

Loap, P., Decroocq, J., Birsen, R., Johnson, N., Bouscary, D., & Kirova, Y. (2025) · Cancer/Radiothérapie · doi:10.1016/j.canrad.2025.104595 · Cited by 2

Revolutions at the frontline of multiple myeloma treatment: lessons and challenges to finding a cure

Kort, J., Rivera, A., Senigarapu, S., & Driscoll, J. J. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1578529 · Cited by 2

Preclinical efficacy of combination therapy with allogeneic induced pluripotent stem cell-derived invariant natural killer T and α-galactosylceramide-pulsed antigen-presenting cells

Aoki, T., Kobayashi, M., Okoshi, M., Yamaguchi, M., Okura, H., Sasaki, S., Sasako, Y., Kira, S., Chang, Y., Yakushiji‐Kaminatsui, N., et al. (2026) · Stem Cell Research & Therapy · doi:10.1186/s13287-026-04994-7 · Cited by 2

Infectious toxicities associated with bispecific antibodies and CAR-T Cells in multiple myeloma: a systematic review

Benda, M., Reimann, P., Willenbacher, W., Gunsilius, E., Weisel, K. C., Straßl, I., Krauth, M. T., Knop, S., Winder, T., & Steiner, N. (2026) · Annals of Hematology · doi:10.1007/s00277-026-07140-8 · Cited by 2

Current progress of CAR-T-cell therapy for patients with multiple myeloma

Nakashima, T., & Kagoya, Y. (2024) · International Journal of Hematology · doi:10.1007/s12185-024-03794-0 · Cited by 4

An Unusual Case of Low Vision and Anisocoria Considered a Neurological Finding in the Emergency Department: Ocular Siderosis

Özen, O., & Özen, M. İ. (2025) · Turkish Journal of Ophthalmology · doi:10.4274/tjo.galenos.2024.77783 · Cited by 3

Advancements in Multiple Myeloma Therapies: A Comprehensive Review by Disease Stage

Khatib, H. H. E., Abdulla, K., Nassar, L. K., Ellabban, M. G., & Kakarougkas, A. (2025) · Lymphatics · doi:10.3390/lymphatics3010002 · Cited by 2

Identification of RUVBL2 as a novel biomarker to predict the prognosis and drug sensitivity in multiple myeloma based on ferroptosis genes

Tang, S., Long, X., Li, F., Jiang, S., Fu, Y., & Liu, J. (2025) · Hematology · doi:10.1080/16078454.2025.2467499 · Cited by 2

Expert Perspectives on Current Challenges and Emerging Approaches for Multiple Myeloma: Narrative Review of an Inaugural Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma

Chari, A., Bal, S., Ailawadhi, S., Krishnan, A. Y., Patel, K. K., Berdeja, J. G., Garfall, A. L., Callander, N. S., Banerjee, R., Alsina, M., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.03.008 · Cited by 2

A Novel Early Memory-Enriched Allogeneic NKG2D CAR-T Cell Therapy Based on CRISPR/Cas9 Technology for Solid Tumors

Aparicio, C., Queipo, M., Belver, M., Espeso, F., Serna-Pérez, J., Enríquez, L., Acebal, C., Martín‐Muñoz, Á., Valeri, A., Leivas, A., et al. (2025) · Cancers · doi:10.3390/cancers17193186 · Cited by 2

Embracing Myeloma Chimeric Antigen Receptor-T: From Scientific Design to Clinical Impact

Hosoya, H., Rodríguez‐Otero, P., Sidana, S., & Borrello, I. (2023) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_389860 · Cited by 2

Commentary on “Comparative efficacy and safety of PSCA CAR-engineered Vδ1 γδ T cells for immunotherapy of pancreatic cancer”

Bont, D. A. D., Straetemans, T., Sebestyén, Z., & Kuball, J. H. E. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-014199 · Cited by 2

Immunotherapy in multiple myeloma

Cantó, P. A., Arnao-Herráiz, M., & Comos, J. D. L. R. (2024) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2024.05.003 · Cited by 1

Treatment refractoriness and response rates in patients with relapsed/refractory multiple myeloma: a retrospective analysis of real-world data.

Lyu, N., Majd, Z., Fatima, B., Zeng, Z., Chen, H., & Abughosh, S. (2025) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2025.100921 · Cited by 3

CAR-T cell therapy for multiple myeloma: An update on the current state and future potential

Pophali, P. A., Rosenblatt, J. M., & Avigan, D. (2025) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2025.101659 · Cited by 1

How should we choose optimal salvage treatments following BCMA-directed CAR T-cell therapy?

Suresh, A., Pan, D., Lipof, J. J., Kumar, A. D., Arora, S., Sayre, P. H., Wolf, J. L., Martin, T. G., Chari, A., & Chung, A. (2025) · Immunotherapy · doi:10.1080/1750743x.2025.2571392 · Cited by 1

Identification and transformation of novel targets for immunotherapy in multiple myeloma

Wang, Y., Wang, Y., Ma, J., Jing, H., Liu, L., Qiu, L., & Hao, M. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003869 · Cited by 1

Prospects for Development and Commercialisation of Allogeneic CAR-Based Therapies for Autoimmune Disease

Osborne, M., & Maher, J. F. (2025) · Biology · doi:10.3390/biology14121790 · Cited by 1

Designs of the clinical trials aiming at evaluating cell and gene therapy products: A critical appraisal from a literature review

Biard, L., Lévy, V., Chevret, S., Künkele, A., Grunwald, S., Aiuti, A., Møller, B. K., Debets, R., Mielke, S., Eldere, J. V., et al. (2025) · Molecular Therapy Advances · doi:10.1016/j.omta.2025.201651 · Cited by 1

Engineering of induced pluripotent stem cells for the efficient development of non-alloreactive, hypoimmunogenic CD8αβ CAR-T cells

Nianias, A., Katsarou, A., Prins, H. J., Shahrabi, A., van Velzen, C., Henneman, L., Ruiter, R. W. J., Mutis, T., Groen, R. W. J., & Themeli, M. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1757174 · Cited by 1

Determinants of Efficacy and Optimization of Chimeric Antigen Receptor T-Cell Therapy for Treating Multiple Myeloma: Current Status and Future Perspectives

Yasui, H., Doki, N., Yan, W., Imai, K., & Ishida, T. (2026) · Cells · doi:10.3390/cells15040380 · Cited by 2

Graft-versus-host disease after chimeric antigen receptor T-cell therapy

Tan, B. R., & Wang, S. S. Y. (2026) · Blood Immunology & Cellular Therapy · doi:10.1016/j.bict.2026.100047 · Cited by 1

Crosstalk between cytokines and tryptophan metabolism: Therapeutic potential for immune effector cell-associated neurotoxicity syndrome

Wu, J., Li, D., Mei, H., & Hu, Y. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.117949 · Cited by 1

Early data indicate safety of allogeneic CAR T cells

Sidaway, P. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00739-0 · Cited by 1

Universal Updated Phase 1 Data Highlights Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma

Mailankody, S., Matous, J., Liedtke, M., Sidana, S., Oluwole, O. O., Mohan, M., Cruz, J. C., Nath, R., Anwer, F., Rossi, A., et al. (2022) · Blood · doi:10.1182/blood-2022-158231 · Cited by 10

Universal: An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 and the Anti-CD52 ALLO-647 in Relapsed/Refractory Multiple Myeloma

Mailankody, S., Matous, J., Liedtke, M., Sidana, S., Malik, S. A., Nath, R., Oluwole, O. O., Karski, E. E., Lovelace, W., Zhou, X., et al. (2020) · Blood · doi:10.1182/blood-2020-140641 · Cited by 71

Universal Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma

Mailankody, S., Liedtke, M., Sidana, S., Matous, J., Chhabra, S., Oluwole, O. O., Malik, S. A., Kumar, S. K., Nath, R., Anwer, F., et al. (2021) · Blood · doi:10.1182/blood-2021-145572 · Cited by 46

Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)

(2019) · Case Medical Research · doi:10.31525/ct1-nct04093596